GHRP-2 Overview
Category:
Synthetic peptide (growth hormone secretagogue)
How It Works:
Agonist at ghrelin/GHS-R1a receptor → increases GH pulses and downstream IGF-1 signaling
Alternative Names:
Pralmorelin, GHRP-II
Primary Research Focus:
- Growth hormone secretion dynamics
- Appetite signaling,
- Metabolic regulation
- Diagnostic stimulation testing
Potential Risks:
Unregulated use outside clinical settings, hormonal imbalance, mild side effects, limited long-term human safety data
What It Is
GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide developed as a growth hormone secretagogue that activates the ghrelin receptor (GHS-R1a) to trigger endogenous growth hormone (GH) release. It was first developed in the early 1990s as part of research into GH stimulation and is approved in Japan for clinical GH diagnostic testing, though it is not FDA-approved for therapeutic use in most countries.
In research contexts, GHRP-2 is used to study endocrine responses and GH pulsatility and to explore metabolic effects linked to GH/IGF-1 pathways.
How It Works in the Body
GHRP-2 functions primarily as an agonist of the ghrelin receptor (GHS-R1a) found in the hypothalamus and pituitary gland. Activation of this receptor suppresses somatostatin (a GH-inhibiting hormone) and directly stimulates growth hormone release from somatotroph cells, creating a pulsatile GH release pattern instead of continuous elevation.
The surge in GH subsequently promotes IGF-1 production (in liver and peripheral tissues), which plays a major role in anabolic processes such as protein synthesis, tissue maintenance, and metabolic regulation.
In addition, GHRP-2 mimics some of ghrelin’s effects on feeding behavior: appetite stimulation and increased food intake have been observed in human research settings.
GHRP-2 Benefits
Stimulates Natural GH Release
GHRP-2 triggers rapid and potent growth hormone secretion by binding the ghrelin/GHS receptor, producing pulsatile GH elevations within approximately 30–60 minutes after dosing in research settings.
Increases IGF-1 Levels
GH pulses prompt the liver and tissues to increase IGF-1, a key mediator of anabolic and metabolic effects, which supports protein synthesis and cellular repair mechanisms.
Enhances Appetite Drive
Clinical infusion studies show that GHRP-2 increases food intake in healthy adults — similar to the effect of ghrelin — indicating its orexigenic (hunger-stimulating) role.
Supports Lean Mass & Recovery (Research Context)
Studies in GH-deficient populations and lab research suggest GHRP-2 enhances GH secretion and may support lean body mass maintenance and aspects of metabolic recovery in certain conditions.
Diagnostic Utility in Endocrinology
GHRP-2 is used clinically (e.g., Japan) as a stimulus agent to assess pituitary GH and related axis function and to evaluate secondary adrenal or hypothalamo-pituitary responses.
Metabolic Appetite & Weight Effects
In case reports involving long-term intranasal administration, GHRP-2 increased hunger, food intake, and body weight in a severe anorexia nervosa patient, along with improved IGF-1 and physical activity over 14 months, with no obvious side effects observed in that report.
Clinical Studies
- GH Secretion Studies: Multiple research trials demonstrated that GHRP-2 significantly increases GH levels in humans shortly after administration, often 8- to 12-fold compared with baseline in controlled settings.
- Appetite & Metabolic Response: A small human trial showed GHRP-2 infusion increased caloric intake by about 35.9% in healthy males compared to saline, alongside significant GH elevation, highlighting ghrelin-like effects on feeding behavior.
- Endocrine Diagnostics: GHRP-2 stimulation tests are used to differentiate hypothalamo-pituitary disorders, with cortisol and ACTH responses providing diagnostic data in clinical endocrinology research.
- Long-Term Case Report: One year of intranasal GHRP-2 in a chronic anorexia nervosa case produced improved hunger, increased body weight, and enhanced muscle strength without notable adverse effects in that individual.
- GH-Deficient Population: Trials in GH-deficient children showed increased GH secretion and improved growth velocity during GHRP-2 treatment periods, with no significant safety concerns reported in those settings.
Safety, Side Effects, and Considerations
Safety Profile:
Available clinical and research reports suggest GHRP-2 is generally well-tolerated in controlled settings, with adverse events typically mild and moderate, such as flushing, increased appetite, water retention, tingling sensations, and injection site discomfort.
Reported Side Effects Include:
- Increased appetite and hunger
- Facial flushing and mild water retention
- Joint stiffness or tingling sensations
- Mild gastro-intolerance during dose escalation
Key Considerations:
- Limited Human Long-Term Data: Long-term effects beyond short research or individual case reports aren’t well established.
- Hormonal Feedback: Manipulating GH and associated axes can affect other endocrine feedback loops; monitoring is important in research or clinical use.
- Regulatory Status: GHRP-2 is investigational outside approved diagnostic use and may be controlled or restricted in some regions.
- Doping Regulations: GH secretagogues like GHRP-2 are prohibited in competitive sports by WADA.
